Satoshi Hori

No ORCID on file · 3 papers in corpus · active 2025-2026

Study types

  • other 2
  • rct 1

Condition tags

  • endometriosis 2
  • dysmenorrhea 1
  • dyspareunia 1
other 2026
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study
Human reproduction open ·doi:10.1093/hropen/hoag030

STUDY QUESTION: Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months? SUMMARY ANSWER: Efficacy from this extension study complements the r…

rct 2025
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study
Fertility and sterility ·doi:10.1016/j.fertnstert.2025.06.016

OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can …

other 2025
Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials
Human reproduction open ·doi:10.1093/hropen/hoaf025

STUDY QUESTION: How important was the change in lumbar spine (L1-L4), femoral neck, and total hip bone mineral density (BMD) from post-treatment baseline values to 24 months after the end of treatment in PRIMROSE 1 and PRIMROSE 2 study part…